Summary
Signal counts
Assets tracked: 9
Watchlist assets: 6
Registry stop assets: 3
Sponsor overview
M.D. Anderson Cancer Center
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT00506155 | https://clinicaltrials.gov/study/NCT00506857 | https://clinicaltrials.gov/study/NCT04599140 | https://clinicaltrials.gov/study/NCT01101412 | https://clinicaltrials.gov/study/NCT00485485 | https://clinicaltrials.gov/study/NCT00049127 | https://clinicaltrials.gov/study/NCT02225275 | https://clinicaltrials.gov/study/NCT01412307 | https://clinicaltrials.gov/study/NCT00508443 | https://clinicaltrials.gov/study/NCT05320406 | https://clinicaltrials.gov/study/NCT03359954 | https://clinicaltrials.gov/study/NCT03028337 | https://clinicaltrials.gov/study/NCT02727777
Assets
Linked programs
- Avastin: Watchlist Signal (2/5)
- Busulfan: Low Signal (1/5)
- CXCR1/2 Inhibitor SX-682: Watchlist Signal (2/5)
- Edetate Calcium Disodium: Registry Stop Signal (4/5)
- Imatinib Mesylate: Low Signal (1/5)
- Lenalidomide: Registry Stop Signal (4/5)
- Radiation Therapy: Watchlist Signal (2/5)
- Spine Radiosurgery: Low Signal (0/5)
- TAK228: Registry Stop Signal (4/5)